Skip to main content
. 2021 Jul 9;12:686155. doi: 10.3389/fimmu.2021.686155

Figure 3.

Figure 3

Action of drugs targeting small molecular metabolites in rheumatoid arthritis. (A) action of drugs targeting PGs family in rheumatoid arthritis; (B) action of drugs targeting LTs family in rheumatoid arthritis; (C) action of drugs targeting LXs family in rheumatoid arthritis; (D) action of drugs targeting PAF in rheumatoid arthritis. PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGI2, prostaglandin I2; PGJ2, prostaglandin J2; TXA2, thromboxane A2; PGF2α, prostaglandin F2α; DP1, prostaglandin D2 receptor 1; EP4, prostaglandin E receptor 4; TP, prostaglandin TXA2 receptor; FP, prostaglandin PGF2α receptor; IP, prostaglandin PGI2 receptor; LTB4, leukotriene B4; CysLT1, cysteine leukotrienes 1; ALX, lipoxin A4 receptor; FPR-2, formyl peptide receptor-2; PAF, platelet-activating factor; PAFR, platelet-activating factor receptor; iNOS, inducible nitric oxide synthase.